首页> 外文期刊>Cardiovascular therapeutics >Targeting fibrosis for the treatment of heart failure: A role for transforming growth factor-β
【24h】

Targeting fibrosis for the treatment of heart failure: A role for transforming growth factor-β

机译:靶向纤维化治疗心力衰竭:转化生长因子-β的作用

获取原文
获取原文并翻译 | 示例
           

摘要

Chronic heart failure (CHF) is a growing health problem in developed nations. The pathological accumulation of extracellular matrix is a key contributor to CHF in both diabetic and nondiabetic states, resulting in progressive stiffening of the ventricular walls and loss of contractility. Proinflammatory disease processes, including inflammatory cytokine activation, contribute to accumulation of extracellular matrix in the heart. Transforming growth factor-β is a key profibrotic cytokine mediating fibrosis. Current therapeutic strategies do not directly target the profibrotic inflammatory processes occurring in the heart and hence there is a clear unmet clinical need to develop new therapeutic agents targeting fibrosis. Accordingly, strategies that inhibit proinflammatory cytokine activation and pathological accumulation of extracellular matrix (ECM) provide a potential therapeutic target for prevention of heart failure. This review focuses on the therapeutic targeting of TGF-β in the prevention of pathological fibrosis in the heart.
机译:慢性心力衰竭(CHF)是发达国家日益严重的健康问题。细胞外基质的病理积累是糖尿病和非糖尿病状态下CHF的关键因素,导致心室壁进行性硬化和收缩力丧失。促炎性疾病过程,包括炎性细胞因子的激活,有助于心脏中细胞外基质的积累。转化生长因子-β是介导纤维化的关键纤维化细胞因子。当前的治疗策略不直接针对心脏中发生的纤维化炎症过程,因此开发针对纤维化的新治疗剂存在明显的未满足的临床需求。因此,抑制促炎性细胞因子激活和细胞外基质(ECM)病理堆积的策略为预防心力衰竭提供了潜在的治疗靶点。这篇综述集中在TGF-β在预防心脏病理性纤维化中的治疗目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号